“…It has been shown that a 14-gauge automated core biopsy device yields individual core samples weighing an average of 17.7 mg, whereas 14-gauge vacuum-assisted breast biopsy devices average 36.8 mg per core, and 11-gauge vacuum-assisted breast biopsy devices average 94.4 mg per core [35]. It follows that a 9-gauge vacuum-assisted breast biopsy device obtains yet more tissue per core, and Poellinger et al [38] reported an average specimen weight of 132.7 mg for a 9-gauge vacuum-assisted breast biopsy system. Our frequency of ADH after 9-gauge vacuum-assisted breast biopsy (14.8%) is higher than that reported by Lourenco et al [30] (8.4%), who used the same device (Table 3).…”
Section: Eby Et Almentioning
confidence: 99%
“…In addition, Sneige et al [37] described an upgrade rate of only 7% for ADH The use of 9-gauge directional vacuumassisted breast biopsy needles for percutaneous tissue biopsy is increasing. The weight of each sample acquired during a typical 9-gauge vacuum-assisted breast biopsy is significantly greater than that acquired during an 11-gauge vacuum-assisted breast biopsy [38]. A single study by Lourenco et al [30] has provided data on upgrade rates for high-risk or malignant lesions discovered with 9-gauge stereotactic vacuum-assisted breast biopsy.…”
Compared with an 11-gauge vacuum-assisted breast biopsy device, the use of a larger 9-gauge vacuum-assisted breast biopsy needle does not decrease the upgrade rate of ADH. Our frequency of ADH at vacuum-assisted breast biopsy is higher than any previously reported and may reflect regional differences in the incidence of breast cancer or practice patterns of the pathologist.
“…It has been shown that a 14-gauge automated core biopsy device yields individual core samples weighing an average of 17.7 mg, whereas 14-gauge vacuum-assisted breast biopsy devices average 36.8 mg per core, and 11-gauge vacuum-assisted breast biopsy devices average 94.4 mg per core [35]. It follows that a 9-gauge vacuum-assisted breast biopsy device obtains yet more tissue per core, and Poellinger et al [38] reported an average specimen weight of 132.7 mg for a 9-gauge vacuum-assisted breast biopsy system. Our frequency of ADH after 9-gauge vacuum-assisted breast biopsy (14.8%) is higher than that reported by Lourenco et al [30] (8.4%), who used the same device (Table 3).…”
Section: Eby Et Almentioning
confidence: 99%
“…In addition, Sneige et al [37] described an upgrade rate of only 7% for ADH The use of 9-gauge directional vacuumassisted breast biopsy needles for percutaneous tissue biopsy is increasing. The weight of each sample acquired during a typical 9-gauge vacuum-assisted breast biopsy is significantly greater than that acquired during an 11-gauge vacuum-assisted breast biopsy [38]. A single study by Lourenco et al [30] has provided data on upgrade rates for high-risk or malignant lesions discovered with 9-gauge stereotactic vacuum-assisted breast biopsy.…”
Compared with an 11-gauge vacuum-assisted breast biopsy device, the use of a larger 9-gauge vacuum-assisted breast biopsy needle does not decrease the upgrade rate of ADH. Our frequency of ADH at vacuum-assisted breast biopsy is higher than any previously reported and may reflect regional differences in the incidence of breast cancer or practice patterns of the pathologist.
“…MRI-guided VAB was originally performed using an 11-gauge (G) needle. As in stereotactic VAB, MRI-guided vacuum-assisted biopsy has trended toward larger needle gauges (10G-7G), since these allow the collection of the same tissue volume with fewer individual samples [18], thereby possibly shortening the examination time. For stereotactic VAB, the current S3-guideline recommends taking at least 12 10G samples or an equivalent tissue volume if other needle gauges are used [4].…”
Breast MR imaging has become established as?the most sensitive imaging method for diagnosing breast cancer. As a result of the increasing examination volume and improved image quality, the number of breast lesions detected only on MRI and requiring further clarification has risen in recent years. According to the S3-guideline ?Diagnosis, Therapy, and Follow-Up of Breast Cancer? as revised in July 2012, institutions performing breast MRI should provide the option of an MRI-guided intervention for clarification. This review describes the indications, methods and results of MRI-guided interventions for the clarification of breast lesions only visible on MRI. Recent guidelines and study results are also addressed and alternative methods and pitfalls are presented.
Key points:
Citation Format:
“…ßeren Nadelstärken (10 -7G), da dadurch eine Entnahme des gleichen Gewebevolumens mit weniger Einzelproben möglich ist [18] Nach der MRT-VB muss überprüft werden, ob die Gewebeentnahme erfolgreich war, d. h. ob die angezielte Läsion zumindest anteilig entfernt worden ist. Dabei sollte dokumentiert werden, ob die Biopsie repräsentativ, fraglich repräsentativ oder nicht repräsentativ war [5].…”
Die dynamische kontrastangehobene Magnetresonanz-Mammografie (MRM) hat sich als sensi-tivstes bildgebendes Verfahren in der Senologie etabliert [1, 2]. Infolge steigender Untersuchungszahlen und verbesserter Bildqualität hat die Anzahl von MR-tomografisch detektierten, abklä-Übersicht 99 Siegmann-Luz KC et al. Abklärung ausschließlich MRT-detektierbarer … Senologie 2014; 11: 99-105 Zusammenfassung ! Die Mamma-MRT (Magnetresonanztomografie) hat sich als sensitivste bildgebende Methode in der Senologie etabliert. Durch steigende Untersuchungszahlen und verbesserte Bildqualität ist in den letzten Jahren ein Anstieg von abklärungsbedürftigen, ausschließlich MRT-detektierten Mammaläsionen zu verzeichnen. Die im Juli 2012 aktualisierte S3-Leitlinie "Diagnostik, Therapie und Nachsorge des Mammakarzinoms" empfiehlt, dass alle Institute, die diagnostische MR-Mammografien durchführen, die Möglichkeit zur MRT-gestützten interventionellen Abklärung vorhalten sollen. Die vorliegende Übersicht beschreibt Indikationen, Methoden und Ergebnisse MRT-gestützter Interventionen zur Abklärung ausschließlich MRT-sichtbarer Mammaläsionen. Dabei werden aktuelle Leitlinien und Studienergebnisse berücksichtigt und alternative Abklärungsmethoden und Pitfalls aufgezeigt. Kernaussagen▶ Nur MR-tomografisch sichtbare BI-RADS ® -4und -5-Befunde bedürfen einer MRT-Intervention. ▶ Die histologische Sicherung sollte mittels MRTgestützter Vakuumbiopsie erfolgen. ▶ Ist eine MRT-Vakuumbiopsie nicht möglich, sollte eine präoperative MRT-Läsionsmarkierung erfolgen. ▶ Die MRT-gestützte Läsionsmarkierung ist zur Zielvolumenmarkierung größerer Kontrastmittelanreicherungen sinnvoll. ▶ MRT-Verlaufskontrolle 6 -12 Monate nach benigner MRT-Vakuumbiopsie bei BI-RADS ® 4 oder 5.Abstract ! Breast MR imaging is the most sensitive method for breast cancer diagnosis. Owing to increased clinical use and improved image quality of breast MRI the number of suspicious MRI-only lesions is enlarging. Following recent German S3-guidelines every institution in which diagnostic breast MRI examinations were carried out should provide the possibility of MRI-guided breast interventions. This review article summarizes indications, methods and results of MRI-guided breast interventions for the clarification of only MRI-detectable breast lesions. Recent guidelines and study results are addressed and alternative methods and pitfalls are presented.Heruntergeladen von: University of British Columbia. Urheberrechtlich geschützt.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.